WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...
Upstream Bio, Inc. ( (UPB) ) has released its Q3 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its ...
Early preclinical and clinical data for verekitug indicate a potential for even greater efficacy than Tezspire. Upstream Bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback